Alkermes plc. Goodwill, Impairment Loss
Alkermes plc. (ALKS) reported Goodwill, Impairment Loss of $0 for the 7-month period ending 2013-10-31, per its 10-KT filed 2014-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GoodwillImpairmentLoss · last filed 2014-02-27
- 2013-10-31: Goodwill, Impairment Loss 7 month $0.00.
- 2012-10-31: Goodwill, Impairment Loss 7 month $0.00.
| Period end | Goodwill, Impairment Loss 7 month |
|---|---|
| 2013-10-31 | $0.00 10-KT · filed 2014-02-27 |
| 2012-10-31 | $0.00 10-K · filed 2013-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |